Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers

Background: In the first-line treatment of biliary tract cancers (BTCs), XELOX (capecitabine plus oxaliplatin) showed comparable clinical efficacy and safety to gemcitabine and oxaliplatin (GEMOX), with fewer visits and better treatment management. Our study aims to investigate the cost-effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ruijia, Zhang, Yalan, Lin, Kongying, Huang, Defu, You, MaoJin, Lai, Yanjin, Wang, Jinye, Hu, Yingying, Li, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354395/
https://www.ncbi.nlm.nih.gov/pubmed/35935821
http://dx.doi.org/10.3389/fphar.2022.871262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354395/
https://www.ncbi.nlm.nih.gov/pubmed/35935821
http://dx.doi.org/10.3389/fphar.2022.871262

Ejemplares similares